stockrow
Saturday 7 November 2026
Export GENB’s income statement to Excel — free account
Generate Biomedicines, Inc.
GENB Healthcare Biotechnology
Generate Biomedicines, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.9 million, up 55.9% from fiscal 2024.
13.06
0.49
+3.90%
Follow GENB
Alert me
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+2 more TTM periods Free account |
— | — | — | 0.00% | |
| — | — | 0.00% | (90.35%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
— | 0.00% | 0.00% | (57.55%) | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | (5.03) | (4.29) | |
Free Cash Flow |
— | (428.15) | (326.14) | (549.72) | |
Capital Expenditures |
— | (7.86) | 56.80 | (162.01) | |
| Other line items | |||||
Cash ROIC |
0.00% | 109.44% | (31.55%) | (60.09%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 704.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 147.18% | |
Share Based Compensation of Revenue |
— | — | — | 76.54% | |
Interest Coverage |
— | — | — | (241.14) | |
Operating CF/Net income |
— | 0.00 | 0.00 | 1.53 | |
Depreciation/Fixed assets |
— | 0.87 | 0.67 | 0.69 | |
Capex/Depreciation |
— | (0.31) | 3.06 | (8.58) | |
Revenue per Share |
0.00 | — | 0.00 | 0.25 | |
Operating CF per Share |
0.00 | 0.00 | (5.90) | (3.02) | |
Capex per Share |
0.00 | 0.00 | 0.88 | (1.26) | |
Capex to Sales |
— | 0.00 | 0.00 | 4.99 |
Columns are period end dates · fundamentals updated 26 Oct 2026